肺表面活性物质联合盐酸氨溴索治疗早产儿肺透明膜病的临床观察

目的探讨肺表面活性物质联合盐酸氨溴索治疗早产儿肺透明膜病的临床效果和安全性。方法60例患肺透明膜病的早产儿随机分为观察组30例和对照组30例；在常规治疗的基础上，观察组加用肺表面活性物质联合盐酸氨溴索治疗，对照组给予盐酸氨溴索治疗，观察两组患儿的疗效和不良反应等。结果观察组患儿呼吸困难减轻、PaO2、PaCO2和住院时间等方面与对照组比较，差异有统计学意义（P〈0．05）。结论肺表面活性物质联合盐酸氨溴索治疗早产儿肺透明膜病，可减轻病情，缩短氧疗时间，减少住院天数。

Objective To explore the clinical efficacy and safety of the pulmonary surfactant and ambroxol in treating premature with pulmonary hyaline membrane disease. Method 60 cases premature with pulmonary hyaline membrane disease were randomly divided into intervention group （30 cases） and control group（30 cases） , the two groups received the same conventional treatment, in addition,the intervention group was treated with the pulmonary surfactant and ambroxol, while the control group was treated with the ambroxol, and then the therapeutic effect and adverse reactions of two groups were observed and compared. Results Dyspnea in the prematures treated by the pulmonary surfactant and ambroxol were improved, PaCO2 and hospital stay were decreased and PaO2 was significantly increased in treatment group than those control group （ P 〈 0. 05 ）. Conclusion The pulmonary surfactant and ambroxol in treating premature with pulmonary hyaline membrane disease could significantly improve the prognosis, shorten oxygen therapy and hospital stay, and hence is worthy of being recommended in clinical practice.